"Next-Gen Technologies in Pharma Sector"

Small can be Mighty -Jenburkt’s Favipiravir @Rs35

Jenburkt, a 120 crore pharma company has proven that small can be mighty. It has launched Favivent its brand of Favipiravir almost at a generic price of Rs.39 a tablet compared to the biggies with Rs.75 a tablet. Hats off to Ashish Bhuta the MD and CEO of Jenburkt Pharmaceuticals Limited who said “Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, if we as a pharmaceutical company cannot make a significant positive difference to the society, our company's very existence is inconsequential”. Earlier this year, the Drug Controller General of India (DCGI) had approved the use of Favipiravir — an antiviral drug developed in Japan and commonly used for treating influenza — for the treatment of mild to moderate cases of COVID-19 in India.

Why Digital Entrepreneurship?